Quarterly ResultAug 3, 2026, 04:28 PM
Indivior Q2 Net Income $122M, up 578%; Repurchases $300M Shares
AI Summary
Indivior Pharmaceuticals reported strong second-quarter results with net income soaring to $122 million, a 578% increase year-over-year, on net revenue of $343 million. For the six months, net income reached $211 million, up 225%. The company also issued $500 million in Convertible Senior Notes, used to repay $333 million of prior debt, and executed $300 million in share repurchases under its $400 million program.
Key Highlights
- Net income for Q2 2026 increased 578% to $122 million from $18 million in Q2 2025.
- Net revenue for Q2 2026 rose 13.6% to $343 million from $302 million in Q2 2025.
- Diluted EPS for Q2 2026 was $0.98, up from $0.14 in Q2 2025.
- Issued $500 million Convertible Senior Notes due 2031 and repaid $333 million of prior debt.
- Repurchased $300 million of common stock, including a $175 million accelerated share repurchase.
- US SUBLOCADE net revenue for six months increased to $455 million from $359 million.
- Completed redomiciliation to the U.S. on January 26, 2026.
Price Impact
More from INDV